Is telehealth allowed to prescribe Mounjaro in California?

If you’re considering GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight management, you might be wondering: Can I actually get these prescribed through telehealth? The short answer is yes—in most cases, you can legally receive a prescription for weight loss medication through a virtual appointment with a licensed healthcare provider.

But as with many things in healthcare, the details matter. Federal regulations, state-specific laws, and provider qualifications all play a role in determining your access to these medications through telehealth. This comprehensive guide breaks down everything you need to know about getting weight loss medication online in 2025.

Understanding Federal Telehealth Rules for Weight Loss Medications

Here’s the most important thing to understand: GLP-1 weight loss medications are not controlled substances. This distinction is crucial because it means they’re not subject to the strict in-person examination requirements that apply to medications like Adderall or opioids under the Ryan Haight Act.

The Ryan Haight Act, a federal law designed to prevent online ‘pill mills,’ requires an in-person medical evaluation before prescribing controlled substances via telemedicine. However, this law does not apply to non-controlled medications like semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro).

Current Federal Status (As of December 2025)

The Drug Enforcement Administration (DEA) has extended COVID-era telehealth flexibilities for controlled substances through December 31, 2025. While this extension primarily affects medications like buprenorphine for opioid use disorder or stimulants for ADHD, it reflects a broader federal embrace of telemedicine that has made virtual care more accessible across all medical specialties—including obesity treatment.

For weight loss medications specifically, there has been no federal restriction on telehealth prescribing since these drugs entered the market. A licensed healthcare provider can evaluate you via video consultation and electronically send your prescription to a pharmacy, as long as they establish a proper patient-provider relationship and meet the standard of care.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-Specific Requirements: Where the Details Get Complicated

While federal law permits telehealth prescribing of weight loss medications, state regulations vary significantly. Some states have additional requirements that affect how you can access these treatments online.

States Requiring an Initial In-Person Visit

Several states mandate that patients have at least one in-person examination before or shortly after beginning weight loss medication treatment:

Arkansas maintains some of the strictest telehealth rules in the country. Providers must perform an initial in-person physical exam to establish the patient-provider relationship before prescribing weight loss medications via telehealth for ongoing care.

Georgia recently updated its laws to allow Nurse Practitioners and Physician Assistants to prescribe Schedule II controlled substances (a significant expansion), but still requires an initial in-person exam for weight management medications. However, follow-up appointments and prescription renewals can occur via telehealth.

Delaware permits telehealth prescribing but requires providers to conduct a physical examination in person before initiating treatment with GLP-1 agonists. Once this initial visit is complete, subsequent monitoring can happen virtually.

Mississippi follows similar guidelines, requiring an initial in-person evaluation for weight management therapy. The state is considering legislation to expand Nurse Practitioner independence, which could streamline telehealth access in the future.

New Jersey has particularly comprehensive requirements. State medical board rules mandate an extensive initial evaluation including physical examination, laboratory work, psychological screening, and documentation of a personalized diet and exercise plan before prescribing any weight-loss medication.

North Dakota expects a hands-on initial evaluation for weight-loss treatment, though the state is otherwise very telehealth-friendly. After the initial visit, virtual follow-ups are standard practice.

South Carolina requires patients to be examined in person initially and mandates periodic in-person evaluations throughout treatment. Nurse Practitioners and Physician Assistants can prescribe with physician oversight.

Texas takes a cautious approach, with medical practice standards generally expecting an initial in-person exam before telehealth prescribing of weight-loss medications. Texas also maintains strict oversight of Nurse Practitioner prescribing—NPs must have a formal physician agreement and cannot practice independently.

Utah encourages an initial in-person exam, though the state recently expanded Nurse Practitioner autonomy (as of 2023), making telehealth more accessible through various provider types.

Virginia has detailed Board of Medicine regulations requiring an initial physical exam, laboratory work, and a personalized diet and exercise plan for any weight-loss drug prescription. The state also mandates a follow-up visit within 30 days of starting therapy, though this follow-up can occur via telehealth.

States with No In-Person Requirement

Many states allow the entire weight loss treatment process—from initial consultation through ongoing care—to occur via telehealth:

California explicitly permits telehealth exams to satisfy the requirement for establishing a patient-provider relationship. With full Nurse Practitioner independence (after three years of experience), California offers robust telehealth access.

Connecticut has permanent telehealth laws with no in-person mandate, though providers must include behavioral counseling and diet/exercise planning as part of obesity treatment.

Florida doesn’t require in-person exams for telehealth prescribing, but does impose specific conditions: patients must have a BMI of 30 or higher (or 27+ with comorbidities) and must be seen at least once every three months during treatment. These quarterly visits can occur via telehealth.

Illinois has no special restrictions on telehealth weight-loss prescribing beyond standard of care. The state requires e-prescribing for all medications, which actually makes telehealth more seamless.

New York allows telehealth exams to establish care, with no unique barriers for weight-loss medications. Nurse Practitioners can practice independently after 3,600 hours of experience, expanding telehealth provider availability.

Pennsylvania permits full telehealth prescribing with no in-person mandate, though Nurse Practitioners still require physician collaboration (pending regulations may eventually grant full practice authority).

Washington is a pioneer in telehealth with no in-person requirements and full Nurse Practitioner independence. The state’s ‘My Health My Data Act’ does add privacy obligations for telehealth providers handling sensitive weight-loss information.

Who Can Prescribe Weight Loss Medications Via Telehealth?

Understanding provider qualifications is essential, especially since you may encounter different types of healthcare professionals in telehealth settings.

Physicians (MDs and DOs)

All states allow licensed Medical Doctors (MDs) and Doctors of Osteopathic Medicine (DOs) to prescribe GLP-1 weight loss medications via telehealth, provided they’re licensed in the state where the patient is physically located during the consultation.

Nurse Practitioners (NPs)

As of December 2025, 34 states plus Washington, D.C. grant Nurse Practitioners full practice authority, meaning they can evaluate patients, diagnose conditions, and prescribe medications—including weight loss drugs—without physician oversight after meeting experience requirements (typically 2-3 years of collaborative practice).

States with independent NP practice include: California, Washington, New York, Connecticut, Virginia (after 2 years), Utah, North Dakota, and many others.

States requiring collaborative practice (NP must have a physician agreement) include: Texas, Florida, Georgia, Arkansas, South Carolina, Mississippi, Pennsylvania, New Jersey, and Illinois.

The trend is clearly moving toward greater NP independence. Recent legislative changes in Georgia (allowing NPs to prescribe Schedule II medications with delegation) and ongoing bills in Mississippi signal continued expansion of NP prescribing authority.

Physician Assistants (PAs)

Physician Assistants can prescribe weight loss medications in all states, but always operate under some level of physician oversight (either supervision or collaboration, depending on state law). The scope varies by state—for example, Texas PAs require formal physician delegation agreements, while some states allow PAs more autonomy in their prescribing within established protocols.

The Patient Perspective: What to Expect from Telehealth Weight Loss Treatment

Initial Consultation Process

Reputable telehealth providers follow a thorough evaluation process:

1. Medical History Review: Expect to complete a detailed questionnaire covering your weight history, previous weight loss attempts, current medications, allergies, and medical conditions.

2. Live Video Consultation: A licensed provider will meet with you via secure video to discuss your health goals, review your medical history, calculate your BMI, and assess whether you’re a good candidate for medication.

3. Clinical Criteria Assessment: Generally, you’ll need a BMI of 30 or higher (or 27+ with weight-related health conditions like type 2 diabetes, hypertension, or sleep apnea) to qualify for GLP-1 medications.

4. Risk Screening: Providers will screen for contraindications including personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia syndrome type 2 (MEN2), pregnancy or pregnancy planning, active gallbladder disease, history of pancreatitis, or severe gastrointestinal disorders.

5. Informed Consent: You’ll receive information about potential side effects (nausea, vomiting, diarrhea, constipation, potential gallstone formation) and the importance of combining medication with lifestyle changes.

6. Treatment Plan: Your provider will develop a personalized plan that includes the medication, dietary guidance, exercise recommendations, and a follow-up schedule.

Ongoing Monitoring and Follow-Up

Weight loss medication isn’t a ‘set it and forget it’ treatment. Responsible telehealth programs include:

• Regular Check-Ins: Typically at 1 month after starting, then every 2-3 months to monitor weight loss, adjust dosage, and assess side effects.

• Lab Work: Periodic laboratory tests (metabolic panel, hemoglobin A1C if you have diabetes) to ensure the medication isn’t causing adverse effects.

• Dose Titration: GLP-1 medications usually start at a low dose and gradually increase to minimize side effects and optimize results.

• Lifestyle Support: Many programs offer nutritional counseling, exercise coaching, or behavioral support alongside medication.

State-Mandated Follow-Up Requirements

Some states have specific follow-up rules:

• Florida: Requires at least one visit every three months during treatment (can be via telehealth).
• Virginia: Mandates a follow-up within 30 days of starting medication (telehealth acceptable).
• Connecticut: Requires behavioral counseling as part of obesity treatment.

Klarity Health incorporates these state-specific requirements into our treatment protocols, ensuring you receive care that meets both clinical best practices and regulatory standards.

Understanding the Medications: What Can Be Prescribed Via Telehealth

Wegovy (Semaglutide 2.4mg)

FDA Status: Approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.

Schedule Status: Not a controlled substance; fully prescribable via telehealth under federal law.

Typical Supply: Initial prescriptions often cover 4 weeks to assess tolerance. Subsequent prescriptions may be for 1-3 months depending on state regulations and insurance requirements.

Important 2025 Update: The FDA declared the Wegovy shortage resolved and banned routine compounding of semaglutide for weight loss effective May 2025. This means legitimate telehealth providers now prescribe only FDA-approved, brand-name Wegovy (or generic equivalents when available), not compounded versions from specialty pharmacies.

Ozempic (Semaglutide 0.5-1mg)

FDA Status: Approved for type 2 diabetes management; commonly used off-label for weight loss.

Telehealth Considerations: Legally prescribable via telehealth, but providers must document the off-label use rationale and obtain informed consent. Many insurance plans won’t cover Ozempic for weight loss alone, so cash-pay pricing becomes relevant.

Same Active Ingredient as Wegovy: Semaglutide works the same way regardless of brand name. Never use Ozempic and Wegovy together, as this would be an unsafe duplication of the same drug.

Mounjaro (Tirzepatide) and Zepbound

FDA Status: Mounjaro is approved for type 2 diabetes; Zepbound (same medication, different dosing) is FDA-approved specifically for obesity.

Dual Action: Tirzepatide acts on both GLP-1 and GIP receptors, often producing more significant weight loss than semaglutide alone in clinical trials.

Telehealth Access: Fully prescribable via telehealth as a non-controlled medication. Insurance coverage varies, but telehealth providers can prescribe for either diabetes management or weight loss depending on patient qualifications.

Red Flags: How to Spot Illegitimate Telehealth Weight Loss Services

The popularity of GLP-1 medications has unfortunately attracted some questionable operators. Protect yourself by watching for these warning signs:

Guaranteed Prescriptions Without Proper Evaluation

Any service that promises you’ll ‘definitely get a prescription’ before you’ve even had a consultation is a major red flag. Legitimate providers evaluate each patient individually and may determine that medication isn’t appropriate for your situation.

Compounded or ‘Custom’ Formulations

Since the FDA banned compounded semaglutide in May 2025, any telehealth service offering compounded versions of Wegovy or Ozempic is operating outside regulatory guidelines. These products may not meet safety and quality standards.

Overseas or ‘Generic’ Versions

FDA-approved semaglutide and tirzepatide are only available from licensed U.S. pharmacies. Services offering to ship medications from overseas pharmacies are illegal and potentially dangerous—you have no guarantee of what’s actually in those vials.

No Follow-Up or Monitoring

Responsible weight loss treatment requires ongoing monitoring. If a service offers a one-time consultation with automatic refills and no check-ins, they’re not following medical standards of care.

Lack of Provider Transparency

You should always know who your prescriber is, what their credentials are, and what state they’re licensed in. Services that hide provider information or use unlicensed ‘medical consultants’ instead of licensed providers should be avoided.

Skipping Informed Consent

Legitimate providers will thoroughly discuss risks, benefits, and alternatives before prescribing. If a service rushes through this process or doesn’t clearly explain side effects and contraindications, look elsewhere.

How Klarity Health Approaches Telehealth Weight Loss Treatment

At Klarity Health, we’ve designed our weight loss program to meet the highest standards of clinical care while maximizing convenience and accessibility.

Licensed Providers in Your State

We employ or contract with physicians, Nurse Practitioners, and Physician Assistants who are specifically licensed in your state. This ensures compliance with state-specific regulations and allows your provider to have a comprehensive understanding of local requirements.

Comprehensive Initial Evaluation

Our intake process includes detailed medical history, risk screening, and a live video consultation with a licensed provider. We calculate your BMI, review your weight loss history, assess for contraindications, and ensure you understand both the benefits and risks of treatment.

State-Specific Compliance

We’ve mapped all 50 states’ telehealth regulations and adjust our protocols accordingly. If your state requires an in-person visit initially, we’ll connect you with a local provider for that exam before beginning telehealth follow-ups. In states without that requirement, we can conduct your entire treatment journey virtually.

Transparent Pricing and Insurance Options

We accept insurance from major carriers and also offer straightforward cash-pay pricing. Before you commit to treatment, you’ll know exactly what your costs will be—no surprise bills or hidden fees.

Integrated Lifestyle Support

Medication is just one part of effective weight management. Our program includes nutritional guidance, exercise recommendations, and behavioral support to help you achieve sustainable results.

Regular Monitoring and Adjustment

We schedule follow-up appointments according to clinical best practices and your state’s requirements. Your provider will monitor your progress, adjust your dosage as needed, and address any side effects promptly.

Provider Availability

One of the most common barriers to weight loss treatment is difficulty getting appointments with specialists. Klarity offers flexible scheduling, including evening and weekend appointments, so you can fit treatment into your life rather than rearranging your life around treatment.

Insurance Coverage and Cost Considerations

Insurance Coverage for Weight Loss Medications

Coverage for GLP-1 medications varies significantly:

• Medicare: Traditional Medicare Part D plans often don’t cover weight loss medications (though coverage for diabetes management is standard). Some Medicare Advantage plans do offer obesity medication coverage.

• Commercial Insurance: Many employer-sponsored plans now cover Wegovy or Zepbound, especially if you have documented weight-related health conditions. Prior authorization is typically required.

• Medicaid: Coverage varies by state. Some states have expanded Medicaid coverage for obesity treatment, while others exclude weight loss medications.

Cash-Pay Options

For patients without insurance coverage, cash-pay pricing is available. While brand-name GLP-1 medications are expensive (often $1,000+ per month), some strategies can help:

• Manufacturer Savings Programs: Novo Nordisk and Eli Lilly offer savings cards that can significantly reduce out-of-pocket costs for eligible patients.

• Telehealth Subscription Models: Some telehealth providers offer bundled pricing that includes provider visits, medication, and support services for a monthly fee.

At Klarity Health, we’re transparent about costs upfront and can help you explore all available options for making treatment affordable.

The Future of Telehealth Weight Loss Treatment

Regulatory Trends to Watch

Permanent Telehealth Legislation: The bipartisan TREATS Act, reintroduced in October 2025, would make certain telehealth prescribing flexibilities permanent. While focused on controlled substances, its passage would signal strong congressional support for expanded telemedicine.

DEA Rule Finalization: The DEA’s temporary telehealth extension for controlled substances expires December 31, 2025. A fourth extension or new permanent rule is expected. While this doesn’t directly affect weight loss medications, it reflects the broader trajectory of telehealth policy.

State Law Evolution: Multiple states have pending legislation to expand Nurse Practitioner independence and streamline telehealth requirements. Mississippi, Pennsylvania, and others are considering full practice authority bills that would expand access to care.

Clinical Developments

New Medications: Several next-generation weight loss medications are in late-stage trials, including oral GLP-1 agonists (eliminating the need for injections) and triple-agonist medications that may produce even better results.

Expanded Indications: Research continues on using GLP-1 medications for conditions beyond obesity and diabetes, including cardiovascular disease prevention and addiction treatment.

Personalized Treatment: Emerging research on genetic factors affecting GLP-1 response may eventually allow providers to predict which medication will work best for each individual patient.

Frequently Asked Questions

Do I need to have diabetes to get Ozempic via telehealth?

No, but Ozempic is only FDA-approved for type 2 diabetes, so prescribing it for weight loss alone is considered off-label use. Many providers will prescribe it off-label if you meet obesity criteria, but you’ll need to sign an informed consent acknowledging this. Wegovy and Zepbound are FDA-approved specifically for weight management without requiring a diabetes diagnosis.

Can my telehealth provider send my prescription to any pharmacy?

Yes, your provider can send electronic prescriptions to any licensed pharmacy in the United States. However, some specialty pharmacies have more experience with GLP-1 medications and may offer better pricing or support services. Your telehealth provider can recommend pharmacies with good availability and competitive pricing.

What happens if I move to a different state during treatment?

Your provider must be licensed in the state where you’re physically located during telehealth visits. If you move, you’ll need to transfer care to a provider licensed in your new state. Many national telehealth companies (including Klarity Health) have providers licensed in multiple states and can facilitate this transition.

How long do I need to stay on weight loss medication?

GLP-1 medications are generally intended for long-term use. Clinical trials show that most patients regain weight when stopping the medication, so many providers recommend ongoing treatment as long as it remains safe and effective. The decision about treatment duration should be made collaboratively with your provider based on your individual circumstances.

Are there generic versions of Wegovy or Ozempic available?

As of December 2025, semaglutide and tirzepatide are still under patent protection, so no FDA-approved generic versions exist. Compounded versions (which some telehealth companies previously offered) are no longer legal for routine weight loss treatment as of May 2025.

Can I get weight loss medication through telehealth if I’m pregnant or trying to conceive?

No. GLP-1 medications are contraindicated during pregnancy and should be discontinued at least 2 months before attempting to conceive. If you’re pregnant, planning pregnancy, or breastfeeding, these medications are not appropriate, and a telehealth provider should not prescribe them.

Take the Next Step: Access Weight Loss Treatment Through Klarity Health

If you’re struggling with obesity and previous weight loss attempts haven’t succeeded, GLP-1 medications prescribed through telehealth may offer an effective, evidence-based solution. The combination of proven medication and the convenience of virtual care has made weight management more accessible than ever.

Klarity Health makes it simple to get started:

• Schedule a Consultation: Book an appointment with a licensed provider in your state at a time that works for your schedule—including evenings and weekends.

• Get Evaluated: Complete a thorough medical evaluation via secure video to determine if weight loss medication is right for you.

• Receive Your Prescription: If appropriate, your provider will send your prescription electronically to your chosen pharmacy.

• Start Your Journey: Begin treatment with ongoing support, regular check-ins, and the accountability you need to achieve your weight loss goals.

With transparent pricing, acceptance of both insurance and self-pay options, and a commitment to clinical excellence, Klarity Health provides a safe, legal, and effective way to access weight loss treatment from the comfort of your home.

Don’t let location, scheduling challenges, or difficulty finding specialized providers stand between you and effective weight management. Discover how telehealth can help you achieve lasting results.

Ready to take control of your health? Schedule your confidential consultation with Klarity Health today.

Research Currency Statement

Verified as of: December 17, 2025

DEA Rules Status: DEA’s COVID-era telehealth flexibilities remain in effect through December 31, 2025. Non-controlled medications (like GLP-1 agonists) are not subject to the Ryan Haight Act’s in-person rule, so they can be prescribed via telehealth under federal law.

States Verified: AR, CA, CT, DE, FL, GA, IL, MS, NJ, NY, ND, PA, SC, TX, UT, VA, WA (as of Dec 2025)

Sources newer than 2024: 15 of 18 sources (most sources are 2024–2025; older sources used only for baseline context)

⚠️ Flagged for follow-up: Federal telehealth rules for controlled substances are temporary (set to expire 12/31/2025) – an additional extension or new rule is expected. State laws are constantly evolving; watch for any changes in 2026 (e.g., pending NP practice authority bills in states like PA & MS, potential federal legislation like the TREATS Act). Also, FDA oversight on compounded GLP-1 medications tightened in 2025 – ensure compliance with current FDA guidance.

Citations

1. DEA and HHS Extend Telemedicine Flexibilities Through 2025 – U.S. Drug Enforcement Administration official announcement (November 15, 2024) – www.dea.gov

2. COVID-Era Telehealth Prescribing Extended for Controlled Substances – Axios News reporting on DEA telehealth extension (November 18, 2024) – www.axios.com

3. DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025 – McDermott Will & Emery legal analysis (November 18, 2024) – www.mwe.com

4. The Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs – Goodwin Procter LLP healthcare law alert (March 27, 2024) – www.goodwinlaw.com

5. Hims Cuts 4% of Workforce Amid Ban on Weight Loss Drug Copies – Reuters reporting on FDA compounding ban (May 30, 2025) – www.reuters.com

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid